STRO
BEARISH
$31.55
Live
Sutro Biopharma, Inc. · NASDAQ
Target $31.44
(-0.3%)
$5.3
52W Range
$32.58
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$522.7M
P/E
N/A
ROE
N/A
Profit margin
-186.5%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
Sutro Biopharma exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -2.04, indicating negative shareholders' equity. While the stock has experienced a speculative 1-year price surge of 506.7%, this is fundamentally unsupported by a -21.40% decline in year-over-year revenue and deep operating losses (-288.98% margin). The current price of $31.55 has reached the analyst target mean of $31.44, leaving no projected upside despite the 'buy' recommendation. The combination of shrinking revenue and catastrophic health scores suggests the recent price action is decoupled from fundamental value.
Key Strengths
Strong short-term price momentum (+506.7% 1Y)
Healthy liquidity with a Current Ratio of 2.01
Positive analyst sentiment (Buy recommendation from 9 analysts)
Quick Ratio of 1.94 suggests ability to cover short-term liabilities
Recent Q/Q EPS growth improvement (+12.4%)
Key Risks
Critical financial health (Piotroski F-Score 1/9)
Negative shareholders' equity (P/B of -2.04)
Declining top-line growth (-21.40% YoY Revenue)
Severe profitability gaps (Operating Margin -288.98%)
Technical trend is heavily bearish (10/100)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
17
Weak
10
30
40
5
0
AI Verdict
Speculative/High Risk
Key drivers: Catastrophic F-Score, Negative Equity, Revenue Contraction, Price/Fundamental Divergence
Confidence
90%
Value
10/100
P/B -2.04, P/S 5.10
Positives
No standout positives identified.
Watchpoints
- Negative Price/Book
- High P/S (5.10) relative to negative growth
- No Graham Number available due to lack of earnings
Future
30/100
Revenue Growth -21.40%
Positives
- Analyst 'Buy' ratings
Watchpoints
- Negative YoY Revenue Growth (-21.40%)
- Negative Forward P/E
Past
40/100
1Y Return +506.7%, 5Y Return -83.1%
Positives
- Massive 1Y price recovery
Watchpoints
- 5Y change of -83.1%
- Consistent history of earnings misses
Health
5/100
Piotroski F-Score 1/9
Positives
- Current Ratio > 2.0
Watchpoints
- Piotroski F-Score 1/9
- Negative ROA (-23.38%)
- Negative Equity
Dividend
0/100
Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No dividend history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$31.55
Analyst Target
$31.44
Upside/Downside
-0.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for STRO and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
Primary
|
-83.1% | -30.0% | +506.7% | +212.4% | +44.8% | +22.0% |
|
EMBC
Embecta Corp.
Peer
|
-78.3% | -65.2% | -18.7% | -34.0% | -3.8% | +1.0% |
|
NPCE
NeuroPace, Inc.
Peer
|
-38.5% | +219.8% | +43.9% | +41.9% | +8.2% | +5.8% |
|
OFIX
Orthofix Medical Inc.
Peer
|
-70.9% | -30.2% | -4.0% | -14.4% | +8.4% | +5.5% |
|
PIII
P3 Health Partners Inc.
Peer
|
-99.5% | -95.6% | -74.5% | -72.2% | -4.2% | -5.3% |
STR
Sutro Biopharma, Inc.
Primary
5Y
-83.1%
3Y
-30.0%
1Y
+506.7%
6M
+212.4%
1M
+44.8%
1W
+22.0%
EMB
Embecta Corp.
Peer
5Y
-78.3%
3Y
-65.2%
1Y
-18.7%
6M
-34.0%
1M
-3.8%
1W
+1.0%
NPC
NeuroPace, Inc.
Peer
5Y
-38.5%
3Y
+219.8%
1Y
+43.9%
6M
+41.9%
1M
+8.2%
1W
+5.8%
OFI
Orthofix Medical Inc.
Peer
5Y
-70.9%
3Y
-30.2%
1Y
-4.0%
6M
-14.4%
1M
+8.4%
1W
+5.5%
PII
P3 Health Partners Inc.
Peer
5Y
-99.5%
3Y
-95.6%
1Y
-74.5%
6M
-72.2%
1M
-4.2%
1W
-5.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-12.72
PEG Ratio
N/A
P/B Ratio
-2.04
P/S Ratio
5.1
EV/Revenue
3.87
EV/EBITDA
-4.07
Market Cap
$522.7M
Profitability
Profit margins and return metrics
Profit Margin
-186.45%
Operating Margin
-288.98%
Gross Margin
-62.38%
ROE
N/A
ROA
-23.38%
Growth
Revenue and earnings growth rates
Revenue Growth
-21.4%
Earnings Growth
N/A
Q/Q Revenue Growth
-21.35%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
2.01
Strong
Quick Ratio
1.94
Excellent
Cash/Share
$8.54
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-289.0%
Net Margin
-401.5%
Total Assets
$0.2B
Liabilities
$0.3B
Equity
$-0.1B
Debt/Equity
-2.31x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
101%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-23
$-4.88
-10.2% surprise
2025-11-06
$-5.57
-57.0% surprise
2025-08-07
$-1.4
+73.6% surprise
2025-05-08
$-9.1
-44.1% surprise
Healthcare Sector Comparison
Comparing STRO against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Profit Margin
-186.45%
This Stock
vs
-16.16%
Sector Avg
+1053.7%
(Superior)
Revenue Growth
-21.4%
This Stock
vs
142.9%
Sector Avg
-115.0%
(Slower)
Current Ratio
2.01
This Stock
vs
4.65
Sector Avg
-56.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
STRO
Sutro Biopharma, Inc.
|
BEARISH | $522.7M | - | -% | -186.5% | $31.55 | |
|
EMBC
Embecta Corp.
|
NEUTRAL | $525.87M | 3.73 | -% | 12.9% | $8.88 | Compare |
|
NPCE
NeuroPace, Inc.
|
NEUTRAL | $516.79M | - | -158.7% | -21.5% | $15.35 | Compare |
|
OFIX
Orthofix Medical Inc.
|
BEARISH | $516.66M | - | -19.3% | -11.2% | $12.87 | Compare |
|
PIII
P3 Health Partners Inc.
|
BEARISH | $507.93M | - | -6952.6% | -10.1% | $2.5 | Compare |
STRO
Sutro Biopharma, Inc.
BEARISH
Mkt Cap
$523M
P/E
-
ROE
-%
Price
$31.55
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-04 | CHUNG JANE | Chief Executive Officer | Stock Award | 788 | - |
| 2026-03-04 | PAULING DAVID J.D. | General Counsel | Stock Award | 675 | - |
| 2026-03-02 | CHUNG JANE | Chief Executive Officer | Stock Award | 10,938 | - |
| 2026-03-02 | GERBER HANS-PETER PH.D. | Officer | Stock Award | 3,968 | - |
| 2026-03-02 | PAULING DAVID J.D. | General Counsel | Stock Award | 3,698 | - |
| 2025-12-12 | CHUNG JANE | Chief Executive Officer | Stock Award | 2,500 | - |
CHUNG JANE
Chief Executive Officer
2026-03-04
788 shares
PAULING DAVID J.D.
General Counsel
2026-03-04
675 shares
CHUNG JANE
Chief Executive Officer
2026-03-02
10,938 shares
GERBER HANS-PETER PH.D.
Officer
2026-03-02
3,968 shares
PAULING DAVID J.D.
General Counsel
2026-03-02
3,698 shares
CHUNG JANE
Chief Executive Officer
2025-12-12
2,500 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
9 analysts
Citizens
2026-04-17
Market Outperform
Market Outperform
Leerink Partners
2026-04-07
Outperform
Deutsche Bank
2026-03-25
Buy
Buy
Wells Fargo
2026-03-24
Equal-Weight
Overweight
HC Wainwright & Co.
2026-03-24
Neutral
Buy
Citizens
2026-01-20
Market Perform
Market Outperform
HC Wainwright & Co.
2025-12-22
Neutral
Neutral
Past News Coverage
Recent headlines mentioning STRO from our newsroom.
Newest → oldest
No matching news yet.